Round led by Hughes & Company as PatientIQ expands its EHR-integrated network, proprietary benchmarks, and patient reach across additional medical specialties, medical device, and life science companies.

本轮融资由休斯公司（Hughes & Company）领投，PatientIQ 借此将其与电子健康记录（EHR）集成的网络、专有基准测试以及患者覆盖范围扩展至更多医疗专科、医疗器械和生命科学公司。

CHICAGO

芝加哥

,

，

Sept. 3, 2026

2026年9月3日

/PRNewswire/ --

/美通社/ --

PatientIQ

患者智商

, the patient outcomes intelligence platform trusted by more than 870 healthcare organizations and 17 million patients across the United States, today announced it has raised $30 million in Series C funding. The round was led by

，这家深受美国870多家医疗机构和1,700万患者信赖的患者预后智能平台今日宣布完成3,000万美元的C轮融资。本轮融资由

Hughes & Company

休斯公司

, a Chicago-based growth equity firm that invests in healthcare software and technology-enabled service companies. Hughes & Company joins current investors: Health Enterprise Partners and August Capital. Travis Hughes, Founder and Managing Partner of Hughes & Company, will join PatientIQ's Board of Directors..

，这是一家总部位于芝加哥的成长型股权公司，专注于投资医疗健康软件及技术驱动的服务型企业。Hughes & Company 将加入现有投资者 Health Enterprise Partners 和 August Capital 的行列。Hughes & Company 的创始人兼管理合伙人 Travis Hughes 将加入 PatientIQ 的董事会。

The financing accelerates PatientIQ's next phase of growth: deepening its presence across existing specialties and health systems, expanding its real-world evidence platform for medical device and life sciences companies, and building a direct-to-patient commerce experience that connects patients to products and services through its growing marketplace..

此次融资将加速 PatientIQ 进入下一增长阶段：深化其在现有专科领域和医疗体系中的布局，为医疗器械和生命科学公司扩展其真实世界证据平台，并打造直接面向患者的商业体验，通过其不断发展的市场平台将患者与产品和服务连接起来。

'We spent a year studying the patient-reported outcomes space,' said Travis Hughes, Founder and Managing Partner of Hughes & Company. 'What we found in PatientIQ is something rare – a company that helped create and define an entirely new category that has a meaningful impact on quality of care. We are excited to be part of PatientIQ's next chapter of growth.'.

“我们花了一年时间研究患者报告结局领域，”Hughes & Company 的创始人兼管理合伙人 Travis Hughes 表示。“我们在 PatientIQ 身上发现了罕见之物——一家帮助创建并定义了一个全新类别的公司，该类别对护理质量产生了有意义的影响。我们很高兴能参与 PatientIQ 增长的下一个篇章。”

Since its Series B in 2022, PatientIQ has grown its EHR-integrated network from 200 healthcare organizations to more than 870, expanded its patient population on the network to over 17 million, and surpassed 70 million patient outcomes collected. The company serves healthcare organizations across more than 20 medical specialties, and powers automated data collection for leading medical device & life science companies, as well as national clinical registries for the American Academy of Orthopaedic Surgeons (AAOS), American Association of Neurological Surgeons (AANS), and Society for Thoracic Surgeons.

自2022年完成B轮融资以来，PatientIQ已将其与电子健康记录（EHR）集成的网络从200家医疗机构扩展至870多家，网络平台覆盖的患者群体增长至超过1,700万人，累计收集的患者结局数据突破7,000万条。公司为涵盖20多个医学专科的医疗机构提供服务，并为领先的医疗器械和生命科学公司以及美国骨科医师学会（AAOS）、美国神经外科医师协会（AANS）和胸外科医师协会的国家临床注册系统提供自动化数据采集支持。

PatientIQ's cloud-based platform integrates with more than 50 EHR systems – including Epic, Oracle Cerner, and Athenahealth – automating outcomes capture within existing clinical workflows..

PatientIQ 的云平台与超过50种电子健康记录（EHR）系统实现集成——包括 Epic、Oracle Cerner 和 Athenahealth——在现有临床工作流中自动捕获结果数据。

'The reason outcomes data has been so hard to act on in healthcare isn't a lack of will – it's a lack of infrastructure,' said Matthew Gitelis, CEO of PatientIQ. 'Building that infrastructure, specialty by specialty, workflow by workflow, is what PatientIQ has been doing for a decade. This investment is validation that the approach is working, and the fuel to take it much further.'.

“在医疗保健领域，结果数据之所以难以转化为实际行动，并非缺乏意愿，而是缺乏基础设施，”PatientIQ 首席执行官马修·吉特利斯表示。“PatientIQ 十年来一直致力于按专科、按工作流程逐步构建这一基础设施。此次投资既验证了该方法的有效性，也为将其推向更深层次提供了动力。”

The investment comes as CMS expands patient-reported outcome requirements and payers tie reimbursement to demonstrated clinical outcomes. Medical device and life science companies face similar pressure to generate real-world evidence – data that can only come from patients being systematically measured in clinical settings – for regulatory submissions, product differentiation, and post-market surveillance.

此次投资正值CMS（美国医疗保险和医疗补助服务中心）扩大患者报告结局要求，且支付方将报销与经证实的临床结局挂钩之际。医疗器械和生命科学公司面临类似的压力，需要生成真实世界证据——即只能在临床环境中对患者进行系统测量才能获得的数据——用于监管申报、产品差异化以及上市后监测。

PatientIQ is positioned to become the standard for outcomes intelligence, connecting the data health systems, researchers, and industry partners need to measure what works and improve care..

PatientIQ 致力于成为结果智能领域的标准，连接医疗系统、研究人员和行业合作伙伴所需的数据，以衡量有效方法并改善护理。

About Hughes & Company

关于休斯公司

Hughes & Company is a private equity firm focused exclusively on investments in software and technology-enabled services within the healthcare sector. The firm aims to partner with companies to drive growth and innovation, pairing strategic guidance and capital to scale solutions that improve patient outcomes and operational efficiency.

休斯公司（Hughes & Company）是一家私募股权公司，专注于投资医疗保健领域内的软件和技术赋能服务。该公司旨在与企业合作，推动增长和创新，通过提供战略指导和资金，扩大能够改善患者治疗效果和运营效率的解决方案。

.

。

www.hughes-co.com

www.hughes-co.com

.

。

About PatientIQ

关于 PatientIQ

PatientIQ is the leading outcomes intelligence platform, trusted by more than 870 healthcare organizations to collect, analyze, and improve patient outcomes. With over 70 million patient-reported outcomes gathered from customers including Northwell Health, Sutter Health, Mercy, Advocate Health, Johnson & Johnson, and Zimmer Biomet, PatientIQ turns the patient voice into actionable insights that drive regulatory compliance, financial performance, and clinical impact.

PatientIQ 是领先的结局智能平台，受到超过 870 家医疗保健组织的信赖，用于收集、分析和改善患者结局。该平台已从 Northwell Health、Sutter Health、Mercy、Advocate Health、强生（Johnson & Johnson）和捷迈邦美（Zimmer Biomet）等客户处收集了超过 7,000 万份患者报告结局（PROs），将患者的声音转化为可操作的洞察，从而推动监管合规、财务绩效和临床影响的提升。

.

。

www.patientiq.io

www.patientiq.io

SOURCE PatientIQ

来源 PatientIQ

21

二十一

%

%

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示